42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
8 citations,
December 2022 in “Nature Reviews Endocrinology” Sex hormones' effects on COVID-19 are unclear and more research is needed to understand their potential as treatment.
3 citations,
August 2022 in “International Journal of Molecular Sciences” COVID-19 can cause hair loss, and treatments like PRP and stem cells might help.
2 citations,
March 2023 in “Experimental neurology” Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.
1 citations,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
1 citations,
March 2022 in “Irish Journal of Medical Science” Men with androgenetic alopecia and hypertension may experience more severe COVID-19.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.